Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Berton Dominique) > Measuring what matt...

King, Madeleine T.Univ Sydney, Australia; Univ Sydney, Australia (författare)

Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer

Artikel/kapitelEngelska2018

Förlag, utgivningsår, omfång ...

2017-12-16
SPRINGER,2018
printrdacarrier

Nummerbeteckningar

LIBRIS-ID:oai:DiVA.org:liu-144892
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-144892URI
https://doi.org/10.1007/s11136-017-1729-8DOI
http://kipublications.ki.se/Default.aspx?queryparsed=id:137488064URI

Kompletterande språkuppgifter

Språk:engelska
Sammanfattning på:engelska

Ingår i deldatabas

SwePubSwePub

Klassifikation

Ämneskategori:ref swepub-contenttype
Ämneskategori:art swepub-publicationtype

Anmärkningar

Funding Agencies|NHMRC [1063012, 570,893]; Target Ovarian Cancer [UCL-P001AL]; Cancer Research UK [C444/A15953]; UCL Cancer Trials Centre [C444/A15953]; Australian Government through Cancer Australia; NHMRC; Department of Health
Gynecologic Cancer Intergroup Symptom Benefit Study (GCIG-SBS) Stage 2 aimed to review, revise, and validate a patient-reported outcome measure (PROM), the Measure of Ovarian Symptoms and Treatment concerns (MOST), developed in GCIG-SBS Stage 1 (MOSTv1, 35 items), and document recurrent ovarian cancer (ROC) symptom burden and benefit. GCIG-SBS Stage 2 recruited patients with platinum-resistant/refractory ROC (PRR-ROC) or potentially platinum-sensitive ROC with aeamp;lt;yenamp;gt; 3 lines of prior chemotherapy (PPS-ROC aeamp;lt;yenamp;gt; 3). Patients completed MOSTv1, QLQ-C30, QLQ-OV28, and FACT-O/FOSI at baseline and before cycle 3 of chemotherapy (pre-C3), and global assessments of change (MOST-Change) pre-C3. Clinicians rated patients cancer-related symptoms, performance status, and adverse events. Convergent and divergent validity (Spearmans correlations), discriminative validity (effect sizes between groups classified by clinician-rated characteristics), and responsiveness (paired t tests in patients expected to experience clinically meaningful change) were assessed. Of 948 recruits, 903 completed PROMs at baseline and 685 pre-C3. Baseline symptom burden was substantial for PRR-ROC and PPS-ROC aeamp;lt;yenamp;gt; 3. MOSTv2 has 24 items and five multi-item scales: abdominal symptoms (MOST-Abdo), disease or treatment-related symptoms (MOST-DorT), chemotherapy-related symptoms (MOST-Chemo), psychological symptoms (MOST-Psych), and MOST-Well-being. Correlations confirmed concurrent and divergent validity. Discriminative validity was confirmed by effect sizes that conformed with a priori hypotheses. MOST-Abdo was responsive to improvements in abdominal symptoms and MOST-Chemo detected the adverse effects of chemotherapy. The MOSTv2 validly quantifies patient-reported symptom burden, adverse effects, and symptom benefit in ROC, and as such is fit-for-purpose for clinical trials of palliative chemotherapy in ROC. Further research is required to assess test-retest reliability.

Ämnesord och genrebeteckningar

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Neurologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Neurology hsv//eng
Ovarian cancer; Recurrent ovarian cancer; Platinum sensitive; Platinum resistant; Platinum refractory; Symptom burden; Symptom benefit; Magnitude of clinical benefit; Net health benefit; Patient-reported outcome; PRO; Patient-reported outcome measure; PROM; Quality of life; QOL; Health-related quality of life; HRQOL; HRQL

Biuppslag (personer, institutioner, konferenser, titlar ...)

Stockler, Martin R.ANZGOG, Australia (författare)
OConnell, Rachel L.Univ Sydney, Australia (författare)
Buizen, LukeUniv Sydney, Australia (författare)
Joly, FlorenceCtr Francois Baclesse, France (författare)
Lanceley, AnneUCL, England (författare)
Hilpert, FelixKrankenhaus Jerusalem Hamburg, Germany (författare)
Okamoto, AikouJikei Univ, Japan (författare)
Aotani, ErikoKanagawa Acad Sci and Technol, Japan (författare)
Bryce, JaneIRCCS, Italy (författare)
Donnellan, PaulGalway Univ Hosp, Ireland (författare)
Oza, AmitUniv Toronto, Canada (författare)
Åvall-Lundqvist, Elisabeth,1957-Linköpings universitet,Avdelningen för Kirurgi, Ortopedi och Onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US,Karolinska Inst, Sweden(Swepub:liu)eliav51 (författare)
Berek, Jonathan S.Stanford Comprehens Canc Inst, CA USA (författare)
Sehouli, JalidAGO Study Grp, Germany,Univ Sydney, Australia (författare)
Feeney, AmandaUCL, England (författare)
Berton-Rigaud, DominiqueGINECO, France (författare)
Costa, Daniel S. J.Univ Sydney, Australia (författare)
Friedlander, Michael L.ANZGOG, Australia (författare)
Univ Sydney, Australia; Univ Sydney, AustraliaANZGOG, Australia (creator_code:org_t)

Sammanhörande titlar

Ingår i:Quality of Life Research: SPRINGER27:1, s. 59-740962-93431573-2649

Internetlänk

Hitta via bibliotek

Quality of Life Research (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Neurologi

Artiklar i publikationen: Quality of Life ...

Av lärosätet: Linköpings universitet; Karolinska Institutet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se